Perceptive Advisors’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Perceptive Advisors’s Portfolio OMIC Stock Details OMIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50,896	Closed	-$798K	–	128
2024 Q3	$798K	Sell	50,896 -20,000	-28%	-$178K	0.02%	101
2024 Q2	$599K	Hold	70,896	–	–	0.01%	105
2024 Q1	$1.09M	Hold	70,896	–	–	0.02%	104
2023 Q4	$979K	Sell	70,896 -7,878	-10%	-$93.2K	0.02%	93
2023 Q3	$900K	Hold	78,774	–	–	0.03%	89
2023 Q2	$1.96M	Sell	78,774 -30,635	-28%	-$898K	0.06%	82
2023 Q1	$3.97M	Hold	109,409	–	–	0.12%	78
2022 Q4	$6.6M	Sell	109,409 -8,467	-7%	-$567K	0.19%	67
2022 Q3	$8.84M	Hold	117,876	–	–	0.26%	69
2022 Q2	$13.5M	Sell	117,876 -3,964	-3%	-$465K	0.42%	53
2022 Q1	$23.1M	Buy	121,840 +10,713	+10%	+$2.48M	0.46%	52
2021 Q4	$38.5M	Buy	111,127 +8,666	+8%	+$3.36M	0.59%	44
2021 Q3	$34.4M	Sell	102,461 -301	-0.3%	-$154K	0.5%	48
2021 Q2	$84.7M	Buy	+102,762	New	+$79.6M	1.1%	24

Other funds holding OMIC

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors's OMIC Position: Q4 2024 in Review

Perceptive Advisors sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q4 2024, closing a stake of 50,896 shares — an estimated $798K sold.

Perceptive Advisors first reported a position in OMIC in Q2 2021 and held it in 14 quarters. The position peaked at $84.7M in Q2 2021. 20 funds tracked by Wall St. Rank hold OMIC as of Q4 2024.

Perceptive Advisors reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Perceptive Advisors sold 50,896 Singular Genomics Systems, Inc. Common Stock shares in Q4 2024, an estimated $798K.
Perceptive Advisors first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 14 quarters.
Perceptive Advisors's Singular Genomics Systems, Inc. Common Stock position peaked at $84.7M in Q2 2021.
20 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q4 2024.

Based on Perceptive Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.